v3.26.1
Segment Reporting (Selected Financial Information by Reporting Segment) (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Reporting Information [Line Items]    
Net revenues $ 171,171 $ 170,528
Stock-based compensation expense 9,274 8,393
Interest income (2,400) (2,089)
Interest expense 6,553 6,286
Income tax provision 3,632 5,577
Net income $ 6,420 25,285
Segment Reporting, Other Segment Item, Composition, Description Other segment items primarily include maintenance and repairs expense, travel expense, professional services expense, legal expense, rent expense, product costs, certain overhead expenses, manufacturing cost absorption and variances, inventory provisions, miscellaneous expenses, and foreign currency exchange gains and losses.  
Pharmaceutical products segment    
Segment Reporting Information [Line Items]    
Number of Reportable Segments | segment 1  
Net revenues $ 171,171 170,528
Payroll expense 50,618 49,310
Materials and supplies 12,741 10,479
Clinical trials expense 1,552 948
Depreciation and amortization expense 14,348 13,609
Stock-based compensation expense 9,274 8,393
Consulting and outside services expense 10,362 9,585
Advertising and promotional expense 3,060 3,889
Other segment items 55,011 39,256
Interest income (2,400) (2,089)
Interest expense 6,553 6,286
Income tax provision 3,632 5,577
Net income $ 6,420 $ 25,285